PACS1 Gene Mental Retardation Autosomal Dominant Type 17 Genetic Test
Test Name: PACS1 Gene Mental Retardation Autosomal Dominant Type 17 Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Neurological Disorders
Doctor: Neurologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for PACS1 Gene Mental Retardation, Autosomal Dominant Type 17 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with PACS1 Gene Mental Retardation, Autosomal Dominant Type 17.
Test Details:
The PACS1 gene is associated with mental retardation, autosomal dominant type 17 (MRD17). MRD17 is a genetic condition characterized by intellectual disability and developmental delay. It is inherited in an autosomal dominant manner, meaning that a mutation in one copy of the PACS1 gene is sufficient to cause the condition.
NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that uses advanced sequencing technologies to analyze multiple genes simultaneously. In the case of MRD17, NGS genetic testing can be used to identify mutations or variations in the PACS1 gene that may be responsible for the condition.
NGS genetic testing involves obtaining a DNA sample, usually through a blood or saliva sample, and sequencing the DNA to identify any variations or mutations in the PACS1 gene. This can help in confirming a diagnosis of MRD17 and can also provide valuable information for genetic counseling and family planning.
It is important to note that NGS genetic testing is typically performed by a specialized laboratory and should be ordered and interpreted by a healthcare professional, such as a geneticist or genetic counselor. They can provide more detailed information about the specific testing process, as well as the implications of the test results.
Test Name | PACS1 Gene Mental retardation autosomal dominant type 17 Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Neurological Disorders |
Doctor | Neurologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for PACS1 Gene Mental retardation, autosomal dominant type 17 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with PACS1 Gene Mental retardation, autosomal dominant type 17 |
Test Details |
The PACS1 gene is associated with mental retardation, autosomal dominant type 17 (MRD17). MRD17 is a genetic condition characterized by intellectual disability and developmental delay. It is inherited in an autosomal dominant manner, meaning that a mutation in one copy of the PACS1 gene is sufficient to cause the condition. NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that uses advanced sequencing technologies to analyze multiple genes simultaneously. In the case of MRD17, NGS genetic testing can be used to identify mutations or variations in the PACS1 gene that may be responsible for the condition. NGS genetic testing involves obtaining a DNA sample, usually through a blood or saliva sample, and sequencing the DNA to identify any variations or mutations in the PACS1 gene. This can help in confirming a diagnosis of MRD17 and can also provide valuable information for genetic counseling and family planning. It is important to note that NGS genetic testing is typically performed by a specialized laboratory and should be ordered and interpreted by a healthcare professional, such as a geneticist or genetic counselor. They can provide more detailed information about the specific testing process, as well as the implications of the test results. |